WO2011043830A3 - Procédés, agents et peptides destinés à induire une réponse immunitaire innée dans la vaccination contre le vih - Google Patents

Procédés, agents et peptides destinés à induire une réponse immunitaire innée dans la vaccination contre le vih Download PDF

Info

Publication number
WO2011043830A3
WO2011043830A3 PCT/US2010/002727 US2010002727W WO2011043830A3 WO 2011043830 A3 WO2011043830 A3 WO 2011043830A3 US 2010002727 W US2010002727 W US 2010002727W WO 2011043830 A3 WO2011043830 A3 WO 2011043830A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
peptides
immune response
methods
agents
Prior art date
Application number
PCT/US2010/002727
Other languages
English (en)
Other versions
WO2011043830A2 (fr
Inventor
Dan Littman
Nicolas Manel
Original Assignee
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University filed Critical New York University
Priority to EP10822366.0A priority Critical patent/EP2485759A4/fr
Publication of WO2011043830A2 publication Critical patent/WO2011043830A2/fr
Publication of WO2011043830A3 publication Critical patent/WO2011043830A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne l'amélioration, la modulation ou la stimulation de la réponse immunitaire innée contre le VIH-1 et d'autres pathogènes viraux. Elle concerne en outre la modulation et l'application de modulateurs immunitaires et de peptides pour des vaccins contre le VIH-1 et contre d'autres pathogènes. L'invention concerne des procédés et des moyens destinés à activer une réponse innée contre le VIH-1 en utilisant ou via le peptide ou la protéine de capside du VIH, comprenant la modulation de la liaison de la cyclophiline A à la protéine de capside du VIH et la modulation de la capacité du VIH à activer le facteur de transcription inné majeur IRF3 et l'interféron. La présente invention concerne en outre des procédés et des tests de criblage de composés, d'agents, ou de peptides capables d'améliorer ou d'activer une réponse immunitaire innée, particulièrement contre le VIH-1.
PCT/US2010/002727 2009-10-09 2010-10-12 Procédés, agents et peptides destinés à induire une réponse immunitaire innée dans la vaccination contre le vih WO2011043830A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10822366.0A EP2485759A4 (fr) 2009-10-09 2010-10-12 Procédés, agents et peptides destinés à induire une réponse immunitaire innée dans la vaccination contre le vih

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27875909P 2009-10-09 2009-10-09
US61/278,759 2009-10-09
US40233610P 2010-08-27 2010-08-27
US61/402,336 2010-08-27

Publications (2)

Publication Number Publication Date
WO2011043830A2 WO2011043830A2 (fr) 2011-04-14
WO2011043830A3 true WO2011043830A3 (fr) 2011-06-16

Family

ID=43857331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/002727 WO2011043830A2 (fr) 2009-10-09 2010-10-12 Procédés, agents et peptides destinés à induire une réponse immunitaire innée dans la vaccination contre le vih

Country Status (3)

Country Link
US (1) US9358281B2 (fr)
EP (1) EP2485759A4 (fr)
WO (1) WO2011043830A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9037247B2 (en) * 2005-11-10 2015-05-19 ElectroCore, LLC Non-invasive treatment of bronchial constriction
WO2012168480A1 (fr) * 2011-06-10 2012-12-13 Institut Curie Agents et procédés pour la production d'adjuvants non infectieux dérivés de capsides de vih
US9149519B2 (en) 2012-01-17 2015-10-06 New York University Chimeric human immunodeficiency virus type 1 (HIV-1) with enhanced dendritic cell and macrophage tropism comprising the simian immunodeficiency virus (SIV) minimal Vpx packaging domain
US20170044218A1 (en) * 2014-04-24 2017-02-16 Janssen Sciences Ireland Uc Use of a HIV derived accessory protein for the reactivation of latent HIV
TWI806081B (zh) 2014-07-11 2023-06-21 美商基利科學股份有限公司 用於治療HIV之toll樣受體調節劑
EP3417062B1 (fr) * 2016-02-15 2024-06-26 Temple University - Of The Commonwealth System of Higher Education Excision de séquences d'acides nucléiques rétrovirales
WO2021022185A1 (fr) * 2019-08-01 2021-02-04 Massachusetts Institute Of Technology Polymères de poly(bêta-thioester) et nanoparticules polymères
US11191784B2 (en) * 2020-03-11 2021-12-07 The Trustees Of The University Of Pennsylvania Methods and composition for gene delivery using an engineered viral particle
WO2024124032A1 (fr) * 2022-12-07 2024-06-13 The Regents Of The University Of Colorado Nouveaux variants du vih-1 et leurs procédés d'utilisation dans un modèle de dépistage animal

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773225A (en) * 1994-05-24 1998-06-30 The Trustees Of Columbia University In The City Of New York Screening method for the identification of compounds capable of abrogation HIV-1 gag-cyclophilin complex formation
US5840305A (en) * 1996-03-14 1998-11-24 The Picower Institute For Medical Research Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity
US20060257974A1 (en) * 2002-05-16 2006-11-16 Bavarian Nordic A/S Fusion proteins of HIV regulatory/accessory proteins
US20070104690A1 (en) * 1996-10-17 2007-05-10 Kingsman Alan J Retroviral vectors
US20080045454A1 (en) * 2004-07-06 2008-02-21 Jeremy Luban Polynucleotide encoding a TRIM-cyp polypeptide, compositions thereof, and methods of using same
WO2009026183A1 (fr) * 2007-08-17 2009-02-26 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Utilisation de protéines gag vih/vis chimériques pour optimiser des réponses de lymphocytes t induites par vaccin contre le gag du vih

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1427826B1 (fr) 2001-09-20 2011-04-20 Glaxo Group Limited Vaccins VIH-RT-nef-Gag à DNA avec codons optimisés
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7404950B2 (en) * 2003-02-18 2008-07-29 Baylor College Of Medicine Induced activation in dendritic cell
US20080107683A1 (en) * 2004-11-30 2008-05-08 David Hone Bacterial Packaging Strains Useful for Generation and Production of Recombinant Double-Stranded RNA Nucleocapsids and Uses Thereof
US7803582B2 (en) * 2007-03-17 2010-09-28 Hongzhan Xu Recombinant vector and use in gene therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773225A (en) * 1994-05-24 1998-06-30 The Trustees Of Columbia University In The City Of New York Screening method for the identification of compounds capable of abrogation HIV-1 gag-cyclophilin complex formation
US5840305A (en) * 1996-03-14 1998-11-24 The Picower Institute For Medical Research Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity
US20070104690A1 (en) * 1996-10-17 2007-05-10 Kingsman Alan J Retroviral vectors
US20060257974A1 (en) * 2002-05-16 2006-11-16 Bavarian Nordic A/S Fusion proteins of HIV regulatory/accessory proteins
US20080045454A1 (en) * 2004-07-06 2008-02-21 Jeremy Luban Polynucleotide encoding a TRIM-cyp polypeptide, compositions thereof, and methods of using same
WO2009026183A1 (fr) * 2007-08-17 2009-02-26 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Utilisation de protéines gag vih/vis chimériques pour optimiser des réponses de lymphocytes t induites par vaccin contre le gag du vih

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLGAN ET AL.: "Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization.", J. VIROL., vol. 70, no. 7, July 1996 (1996-07-01), pages 4299 - 4310, XP008155876 *
GATANAGA ET AL.: "Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop.", J. BIOL. CHEM., vol. 281, no. 2, 2006, pages 1241 - 1250, XP008155875 *
See also references of EP2485759A4 *

Also Published As

Publication number Publication date
EP2485759A4 (fr) 2013-07-24
US9358281B2 (en) 2016-06-07
WO2011043830A2 (fr) 2011-04-14
EP2485759A2 (fr) 2012-08-15
US20110159025A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
WO2011043830A3 (fr) Procédés, agents et peptides destinés à induire une réponse immunitaire innée dans la vaccination contre le vih
MX346862B (es) Secuencias consenso de envoltura de vih y método para usar las mismas.
IN2015DN02546A (fr)
EA202090149A1 (ru) Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения
PH12015500931A1 (en) Recombinant particle based vaccines against human cytomegalovirus infection
MX350274B (es) Vacunas para hsv-2.
GB2513768A (en) Complexes of cytomegalovirus proteins
EA201390806A1 (ru) Конструкция пептидного каркаса
WO2007147529A3 (fr) Vaccin viral recombinant
MX2019007921A (es) Nuevos agentes de union a ha.
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
AR071910A1 (es) Vacuna combinada para el papiloma humano y el sarampion. vector. huesped.
EA202090759A3 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
MY162335A (en) Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof
MY149395A (en) Pharmaceutical compound capable of induce immune protective response against dengue virus having the capsid protein of the dengue virus
WO2016191641A3 (fr) Procédés pour améliorer des réponses immunitaires spécifiques à un antigène à l'aide d'une polythérapie comprenant des antigènes de capside de papillomavirus
PL3504225T3 (pl) Nowe antygeny białkowe otoczki ludzkiego wirusa niedoboru odporności eksprymowane przez ssaki
EP2567967A3 (fr) Méthode pour utiliser les vecteurs adénovirals à mener une réponse immunitaire
MX2017014417A (es) Vacunas contra el dengue.
CO6670515A2 (es) Vectores de parapoxvirus
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
EP3599247A3 (fr) Protéine d'hémagglutinine recombinante du virus de la grippe et vaccin la contenant
WO2010121013A3 (fr) Polymères à empreintes moléculaires utilisables à des fins de détection du vih-1
WO2010040572A3 (fr) Anticorps

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10822366

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010822366

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010822366

Country of ref document: EP